Bourgeon Capital Management LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,697 shares of the conglomerate’s stock after selling 1,162 shares during the period. Danaher accounts for approximately 3.3% of Bourgeon Capital Management LLC’s portfolio, making the stock its 9th largest position. Bourgeon Capital Management LLC’s holdings in Danaher were worth $6,098,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of DHR. GQG Partners LLC acquired a new position in shares of Danaher during the second quarter worth $101,000. Zions Bancorporation grew its stake in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares in the last quarter. Patten Group Inc. grew its stake in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares in the last quarter. First Personal Financial Services grew its stake in shares of Danaher by 128.9% during the fourth quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 691 shares in the last quarter. Finally, Calton & Associates Inc. acquired a new position in shares of Danaher during the fourth quarter worth $114,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.
DHR has been the subject of a number of research reports. Citigroup boosted their price target on shares of Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. Robert W. Baird reissued a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Royal Bank of Canada reissued a “hold” rating and issued a $96.00 price target on shares of Danaher in a research report on Thursday, January 4th. Stifel Nicolaus boosted their price target on shares of Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Credit Suisse Group boosted their price target on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $100.13.
In related news, SVP Daniel Raskas sold 37,870 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP William K. Daniel sold 131,066 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the transaction, the executive vice president now directly owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders have sold 274,913 shares of company stock valued at $27,729,293 over the last three months. 12.20% of the stock is currently owned by corporate insiders.
Shares of Danaher Co. (NYSE:DHR) traded up $1.08 during trading hours on Wednesday, hitting $96.06. 953,962 shares of the stock were exchanged, compared to its average volume of 2,854,609. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $104.82. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $66,680.00, a PE ratio of 27.39, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04.
Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The business had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the company earned $1.05 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. equities research analysts forecast that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, January 26th. Investors of record on Friday, December 29th were issued a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.58%. Danaher’s dividend payout ratio is currently 16.00%.
ILLEGAL ACTIVITY NOTICE: “Bourgeon Capital Management LLC Lowers Holdings in Danaher Co. (NYSE:DHR)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/bourgeon-capital-management-llc-has-6-10-million-position-in-danaher-co-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.